Key facts
- This page summarizes Kevin Charles Gorman's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
- 8 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Feb 2026, 17:44.
Kevin Charles Gorman - 13 Feb 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)
- Reporting relationship
- Director
- Issuer ticker
- NBIX
- Reported as of
- 13 Feb 2026
- Net transaction value
- -$5,002,657
- SEC form
- 4
- Accepted by SEC
- 17 Feb 2026, 17:44:32 UTC
- Prior SEC filing
- 03 Feb 2026
- Next SEC filing
- 21 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Darin Lippoldt, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kevin Charles Gorman filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 17 Feb 2026.
Change
- Previous filing in this sequence was filed on 03 Feb 2026.
- Current net transaction value: -$5,002,657.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001201096
Primary reporting owner
GORMAN KEVIN CHARLES
- Relationship
- Director
- Address
- 6027 EDGEWOOD BEND CT., SAN DIEGO
- Signature
- /s/ Darin Lippoldt, Attorney-in-Fact
- Signature date
- 17 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NBIX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +5,604
- Change %
- +1.1%
- Price
- $0.000000
- Shares after
- 522,497
- Date
- 13 Feb 2026
- Ownership
- Direct
NBIX
transaction
Common Stock
Tax liability
- Transaction value
- $375,339
- Shares
- -3,024
- Change %
- -0.58%
- Price
- $124.12
- Shares after
- 519,473
- Date
- 13 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
NBIX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +5,377
- Change %
- +1%
- Price
- $0.000000
- Shares after
- 524,850
- Date
- 13 Feb 2026
- Ownership
- Direct
NBIX
transaction
Common Stock
Tax liability
- Transaction value
- $360,072
- Shares
- -2,901
- Change %
- -0.55%
- Price
- $124.12
- Shares after
- 521,949
- Date
- 13 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
NBIX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +63,724
- Change %
- +12%
- Price
- $0.000000
- Shares after
- 585,673
- Date
- 13 Feb 2026
- Ownership
- Direct
- Footnotes
- F2
NBIX
transaction
Common Stock
Tax liability
- Transaction value
- $4,267,246
- Shares
- -34,380
- Change %
- -5.9%
- Price
- $124.12
- Shares after
- 551,293
- Date
- 13 Feb 2026
- Ownership
- Direct
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NBIX
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -5,604
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 11,208
- Date
- 13 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,604
- Exercise price
- Footnotes
- F4, F5
NBIX
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -5,377
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 5,377
- Date
- 13 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,377
- Exercise price
- Footnotes
- F4, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.
Footnote F2
On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.
Footnote F3
551,293 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.
Footnote F4
Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Footnote F5
This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 5,603 shares on February 13, 2025, vested as to 5,604 shares on February 13, 2026, and will vest as to 5,604 shares on February 13, 2027, and 5,604 shares on February 13, 2028, subject to the terms and conditions of the award.
Footnote F6
This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 5,376 shares on February 13, 2024, vested as to 5,376 shares on February 13, 2025, vested as to 5,377 shares on February 13, 2026, and will vest as to 5,377 shares on February 13, 2027, subject to the terms and conditions of the award.